Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | CETP | P11597 | 4/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | LAP3 | P28838 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22402591 | 0.89 | TSHR (0.70) | TSHRCETPFOLH1SRCPDPK1 | |
| SCHEMBL17170447 | 0.85 | TSHR (0.55) | TSHRCETPFOLH1SRCPDPK1 | |
| SCHEMBL9621949 | 0.85 | TSHR (0.66) | TSHRCETPFOLH1SRCPDPK1 | |
| SCHEMBL22402661 | 0.84 | TSHR (0.63) | TSHRCETPFOLH1SRCPDPK1 | |
| SCHEMBL26361302 | 0.84 | TSHR (0.53) | TSHRCETPFOLH1SRCPDPK1 | |
| SCHEMBL6825537 | 0.81 | TSHR (0.70) | TSHRCETPFOLH1SRCPDPK1 | |
| SCHEMBL12876168 | 0.81 | TSHR (0.59) | TSHRCETPFOLH1SRCPDPK1 | |
| SCHEMBL12567320 | 0.79 | TSHR (0.57) | TSHRCETPFOLH1SRCPDPK1 | |
| SCHEMBL13185883 | 0.79 | TSHR (0.57) | TSHRCETPFOLH1SRCPDPK1 | |
| SCHEMBL28244553 | 0.79 | TSHR (0.68) | TSHRCETPFOLH1SRCPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | TSHR 2816/4885CETP 2787/4885FOLH1 3746/4885 |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | TSHR 2816/4885CETP 2787/4885FOLH1 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.